Current report filing

Cover

v3.22.2
Cover
Jun. 21, 2022
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Pasithea Therapeutics Corp. (the “Company”) filed with the U.S. Securities and Exchange Commission on June 22, 2022 (the “Original Form 8-K”). The Original Form 8-K reported the Company’s acquisition of Alpha-5 Integrin, LLC (“Alpha). The purpose of this amendment is to disclose the Company’s intent to file the financial statements and pro forma financial information of Alpha within 75 days of the close of the transaction. Other than as set forth in this Amendment No.1, no other changes have been made to the Original Form 8-K. The information previously reported in or filed with the Original Form 8-K is hereby incorporated by reference into this Amendment No. 1.
Document Period End Date Jun. 21, 2022
Entity File Number 001-40804
Entity Registrant Name Pasithea Therapeutics Corp.
Entity Central Index Key 0001841330
Entity Tax Identification Number 85-1591963
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1111 Lincoln Road
Entity Address, Address Line Two  Suite 500
Entity Address, City or Town Miami Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33139
City Area Code (702)
Local Phone Number 514-4174
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common stock, $0.0001 par value per share  
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol KTTA
Security Exchange Name NASDAQ
Warrants to purchase shares of common stock, par value $0.0001 per share  
Title of 12(b) Security Warrants to purchase shares of common stock, par value $0.0001 per share
Trading Symbol KTTAW
Security Exchange Name NASDAQ